Panbela Therapeutics, Inc. has filed a revised preliminary proxy statement with the SEC, amending and superseding the original proxy statement filed on April 4, 2024, in connection with the company's rescheduled Special Meeting of Stockholders. The meeting, originally set for May 3, 2024, has been moved to May 28, 2024, with a new record date of April 24, 2024, for stockholder eligibility to vote. The proxy statement details the rescheduling and the issuance of one share of Series A Preferred Stock on April 23, 2024, with specific voting rights. The Special Meeting's agenda includes a proposal to approve a reverse stock split of the company's common stock, with a ratio range between 1-for-10 and 1-for-45, as determined by the board. Additionally, the meeting will consider the approval...Show More

Panbela Therapeutics, Inc. has filed a revised preliminary proxy statement with the SEC, amending and superseding the original proxy statement filed on April 4, 2024, in connection with the company's rescheduled Special Meeting of Stockholders. The meeting, originally set for May 3, 2024, has been moved to May 28, 2024, with a new record date of April 24, 2024, for stockholder eligibility to vote. The proxy statement details the rescheduling and the issuance of one share of Series A Preferred Stock on April 23, 2024, with specific voting rights. The Special Meeting's agenda includes a proposal to approve a reverse stock split of the company's common stock, with a ratio range between 1-for-10 and 1-for-45, as determined by the board. Additionally, the meeting will consider the approval of adjournments if necessary to solicit more proxies in the event of insufficient votes or lack of quorum. Stockholders are urged to use the new proxy card provided for their votes to be counted. The proxy statement and related materials are available online, and stockholders must register by May 25, 2024, to attend the virtual meeting.